Ice Cut

Mixture of clenbuterol Hydrochloride and Yohimbine (HELIOS) & l-carnitine 20ml vial

Each ml contains.

(1) 30 mcg   clenbuterol Hydrochloride

(2) 5   mg    Yohimbine

(3) 200 mg    l-carnitine

Description

(1) Clenbuterol is a ß2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer lasting as a stimulant and thermogenic drug. [citation needed] It is commonly used for smooth muscle-relaxant properties as a bronchodilator and tocolytic.

It is classified by the World Anti-Doping Agency as an anabolic agent, not as a ß2 agonist.

Clenbuterol is prescribed for treatment of respiratory diseases for horses, and as an obstetrical aid in cattle. It is illegal in some countries to use in livestock used for food.

(2) Yohimbine is an indolealkylamine alkaloid that acts primarily by blocking central alpha-2 adrenoreceptors that are stimulated by xylazine. Yohimbine is an alpha-2 adrenergic receptor antagonist that easily penetrates the blood-brain barrier. It competitively blocks and antagonizes central nervous system depression or sedation and the bradycardia and respiratory depression caused by xylazine.

Xylazine, an alpha-2 adrenergic agonist with potent sedative, analgesic and muscle relaxant properties, has been used extensively as an analgesic-sedative restraining agent. It has also been used as a preanesthetic agent for many general anesthetics. The central nervous system depressant effect, as well as other pharmacologic effects, is dose dependent.

Yohimbine is useful to counteract the sedation after standard doses of xylazine. The competitive selective blocking of the alpha-2 adrenergic receptor by yohimbine displaces xylazine from these sites and thereby rapidly cancels the effect of the xylazine.

Yohimbine, when used at the prescribed dose, will effectively reverse the effects of xylazine when it is used alone in dogs. Yohimbine abbreviates the anesthesia and chemical restraint of the xylazine.

The reversal of the sedative effects of xylazine by I.V. injection of yohimbine is rapid, usually occurring within one to three minutes, regardless of the route of administration of xylazine.

(3) Levocarnitine (L-3-hydroxy-4-N-trimethylaminobutyrate) is synthesized in the liver from the amino acids’ methionine and lysine. This naturally occurring substance is found in all mammalian tissues, especially striated muscle, and is required in energy metabolism, such as the oxidation of fatty acids, facilitating the aerobic metabolism of carbohydrates, and enhancing the excretion of certain organic acids. While only the L isomer is present in the biologic system, commercial synthesis of carnitine produces a D, L racemic mixture, from which the L-isomer is obtained. The D-isomer has pharmacologic effects but does not participate in lipid metabolism. Commercially, carnitine is available as both a prescription and non-prescription product. The prescription version is levocarnitine, while most dietary supplements contain D, L-carnitine which is commonly sold in health food stores.

Indications and usage

(1)Clenbuterol Hydrochloride is a sympathomimetic that works on the sympathomimetic nervous system. There are several receptors in the body a sympathomimetic can act on. In the case of Clenbuterol, the beta-2 receptor is the area of interest and action. Clen, as it’s commonly known, actively stimulates the beta-2 receptor. Through such stimulation, this actively reverses airway obstructions and provides improved breathing for those who need it. This same stimulation can also be used to enhance the metabolic rate of the individual. Clenbuterol does not actively burn fat by attacking fat cells, but rather stimulates the metabolism by increasing the body’s temperature. This occurs due to the beta-2 stimulation stimulating the mitochondria of the cells to produce and release more heat. In turn, this heats up the body’s temperature (slightly), enhances the metabolism and causes the individual to burn body fat at a greater rate. In reality, the functions and traits of Clenbuterol are very simple and very straightforward.

Clenbuterol has also been noted for having a strong anabolic effect; however, things are not quite like they appear. Due to the potential anabolic effect, this has caused many to use the compound in hopes of gaining lean tissue. Commonly, many steroid users have used it as an anabolic protective agent during their post cycle therapy (PCT). There is, however, a problem with this type of use; it doesn’t work. Studies have shown that Clenbuterol has the ability to promote anabolic activity in animals. There have been several studies that have shown the anabolic activity of rats to increase when Clen is administered. However, there is no data that supports such anabolic activity provided when used by human beings. In fact, it has generally been proven useless in this regard as it pertains to human beings. When it comes to human Clenbuterol use, use as a bronchodilator and thermogenic are the only suitable purposes.

The effects of Clenbuterol on the asthmatic patient are as straightforward as can be. Use of the bronchodilator opens up the airways and enables the individual to breath. There are other breathing disorders that can benefit from Clenbuterol use, but asthma appears to be primary, and it is often a welcomed medication to those who suffer. This same improved breathing could also prove useful to some athletes, especially those who can benefit from enhanced cardiovascular endurance. However, we’re not talking about a strong, notable improvement and there are truly other methods that are far more suited for increasing cardiovascular endurance.

(2) Yohimbine has been studied as a way to improve the effects of exposure therapy in people with post-traumatic stress disorder (PTSD).

It has also been studied as a potential treatment for erectile dysfunction but there is insufficient evidence to rate its effectiveness. It is illegal in the United States to market an over-the-counter product containing yohimbine as a treatment for erectile dysfunction without getting FDA approval to do so. Nevertheless, the quantity of yohimbine in dietary supplements, often advertised as promoting sexual function, has been found to overlap with prescription doses of yohimbine.

Yohimbine blocks the pre- and post-synaptic α2 receptors. Blockade of post-synaptic α2 receptors causes only minor corpus cavernosum smooth muscle relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2 receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system — thus in the corpus cavernosum — such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1 receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction.

(3)Levocarnitine facilitates long-chain fatty acid transport from the cytosol to the mitochondria, providing substrates for oxidation and subsequent cellular energy production. Levocarnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism or specific organic acidopathies that bioaccumulate acyl CoA esters. Levocarnitine clears the acyl CoA esters by formation of acylcarnitine which is rapidly excreted.

Carnitine acetyltransferases (CATs) catalyze the interconversion of fatty acid esters of coenzyme A and carnitine, which are located in the cytosol and mitochondrial membranes. Translocases, which exist in mitochondrial membranes, rapidly transport both free carnitine and its esters in and out of cells. Fatty acid esters of CoA, formed in the cytosol, inhibit enzymes of the Krebs cycle, and are involved in oxidative phosphorylation. Hence, the oxidation of fatty acids requires the formation of acylcarnitines and their translocation into mitochondria where the CoA esters are reformed and metabolized. If oxygen tension is limited, carnitine serves to maintain a ratio of free to esterified CoA within mitochondria that is optimal for oxidative phosphorylation and for the consumption of acetyl CoA.

Pharmacokinetic and clinical studies have shown that administration of levocarnitine to patients with end-stage renal disease (ESRD) on hemodialysis results in increased plasma levocarnitine concentrations. The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severe renal impairment or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine. The accumulation of these metabolites does not occur to the same extent following intravenous administration (manufacturer information).

Adverse effects

(1)There are several possible side effects to Clenbuterol use, and the primary will surround its stimulating nature. No surprise, after all, Clen is a stimulant. The side effects of Clenbuterol can be very strong and often very annoying to say the least, and they will generally affect most people in one way or another. The most common side effects surround a jittery or wired feeling, shaky hands and increased sweating. Most all who use Clen will experience such effects to a degree, but they will commonly be very pronounced during the early stages of use. As the individual becomes accustomed to the stimulant, such related effects should begin to subside, but they will be so strong in some people that some will not be able to use it.

When using Clenbuterol, many often inaccurately assume that when the stimulating effects of Clen began to fade that the thermogenic effects are no longer working. Most will find that the stimulating effects will greatly subside after a week or so of use, but assuming the fat burning properties have vanished due to this lessened stimulation is highly inaccurate. The same dose of Clenbuterol Hydrochloride can actually keep the metabolism revved for as much as five weeks. Granted, by the fifth week mark it will be minimal as the body does most certainly adapt. Due to the body’s ability to adapt, necessarily adjustments must be made to use. We will go over adjustments, dosing plans and total plans of use in the Clenbuterol in the administration section.

(2) The most commonly reported side effects included gastrointestinal distress, increased heart rate, anxiety and high blood pressure. A few people even experienced life-threatening events, including heart attack, seizure and acute kidney injury.

However, it is worth mentioning that many of these cases resulted from products that contained several other ingredients in addition to yohimbe, which may have contributed to the adverse effects.

(3)Gastrointestinal (GI) adverse effects are possible with oral and intravenous (IV) levocarnitine therapy. These GI symptoms include abdominal pain, dyspepsia, diarrhea, gastritis, nausea, and vomiting. These adverse effects with oral therapy may be reduced by slowing the rate of consumption and administering as divided doses throughout the day. During clinical trials of IV levocarnitine in patients on chronic hemodialysis, GI adverse reactions were reported at the following incidence compared to placebo: abdominal pain (5—21% vs 17%), anorexia (3—6% vs 3%), constipation (3% vs 6%), diarrhea (9—35% vs 19%), dyspepsia (5—9% vs 10%), gastrointestinal disorder (2—6% vs 2%), melena (2—6% vs 3%), nausea (5—12% vs 10%), vomiting (9—21% vs 16%), weight gain (2—3% vs 2%), and weight loss (3—8% vs 3%).

Drug-induced body odor (described as "fishy" odor), headache, paresthesias and weakness have been associated with intravenous as well as oral administration of levocarnitine. During clinical trials of IV levocarnitine in patients on chronic hemodialysis, nervous system adverse reactions were reported at the following incidence compared to placebo: headache (3—37% vs 16%), anxiety (1—2% vs 5%), asthenia (8—12% vs 8%), depression (5—6% vs 3%), dizziness (10—18% vs 11%), drug dependence (2—6% vs 2%), hypertonia (1—3% vs 5%), insomnia (3—6% vs 6%), paresthesias (3—12% vs 3%), and vertigo (2—6% vs 0%)

Do you know anything about HELIOS?!

Helios was originally developed by an idea from the legendary body-building guru Dan Duchaine. Generic Supplements is selling this extremely potent solution on the bodybuilding market. The ingredients (Clenbuterol and Yohimbine HCL) are forbidden in almost every country, as well as administration via injection. This is only allowed by a doctor or medical trained nurse. But this form of administration is also the best way for spot reduction.

The art of spot reduction

When you begin a diet, you may notice that you lose fat very unevenly on your body. The areas you don't wish to concentrate your fat loss seem to be most responsive to the restriction of calories. On the other hand, the areas you desire to shed fat seem to be unaffected by the diet. In women, the breasts may be shrinking, while the lower body remains as fat as it was. In men, even if the waist is getting smaller, the abs are not getting any more visible. Why put your body through a tough and often unhealthy diet if unwanted inches of fat remain? What we want is a specifically targeted fat loss, but we are told that spot reduction is impossible! Is this true?

Rather than an overall and even fat reduction, the weight loss will be more "spot specific". Popular belief is that we cannot spot reduce fat. This is however a myth, because the human body does, but unfortunately it doesn't necessarily do it in the places we wish it to. What we have to do, is to redirect the fat destruction in areas we want to shrink rather than everywhere else. Please realize that your abs are not covered by that much fat. Imagine if one could concentrate the fat loss exclusively in that particular area. It is the same thing for the women who could easily lose their lower body fat by strictly concentrating the fat reduction there.

Best sites for application as mentioned above are the triceps, "love handles", thighs, gluteus and the "saddle bags" or waist (basically any area that has fat accumulation). These areas will vary from person to person, though the above listed are the most common. The fat that fails to disappear even through a strict diet is called "stubborn fat". Typically, so called stubborn fat is estrogenic by nature, however some people just have high numbers of A2 receptors. The A2 receptor is highly influenced by estrogen if you are a woman, and if you have estrogenic fat patterns you most likely have large numbers of A2 receptors.

And now!ICE CUT, the Ice Prolab new fat burning formula! old HELIOS + L CARNITINE

Dosage and Administration

One must start at a low dose to be on the watch for adverse side effects due to the high potency.  0, 5 ML is a recommended starting dose in the morning injected straight into the fat deposit for local fat loss. The dose must be adjusted cautiously. Never exceed 2ML per day! Because the adrenergic receptors will stop its responsiveness.

Sample cycle: (Must be adopted personally)

week 1: 0,5 ML per day

week 2: 1 ML per day

then stop two weeks.

week 5: 0,5 ML per day

week 6: 1 ML per day

repeat breaks and repeat usage.

Storage

Store in cool dry place below 25°c.Protect from light. keep out of reach of children.

Manufactured by: Ice Prolab co Ltd (USA) in PANAMA (Calle 35 Este, Panama, Panama)